1. Spinal and bulbar muscular atrophy Clinical trials / Disease details


Clinical trials : 17 Drugs : 16 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 17

  
7 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-183981
02/11/201701/06/2018Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and bulbar muscular atrophy (SBMA)Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and bulbar muscular atrophy (SBMA) Spinal and bulbar muscular atrophyIntervention name : Leuprorelin Acetate
Dosage And administration of the intervention : Leuprorelin Acetate Injection Kit 11.25 mg, every 12 weeks subcutaneously, for up to at most 8 years. Participants received interventions as part of routine medical care.
TAKEDA PHARMACEUTICAL COMPANY LTD.NULLrecruitingBOTH300NANULL
2NCT03555578
(ClinicalTrials.gov)
November 2, 20171/6/2018Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)Spinal and Bulbar Muscular AtrophyDrug: Leuprorelin AcetateTakedaNULLRecruitingN/AN/AAll300Japan
3JPRN-JMA-IIA00080
02/201226/01/2012Phase 2 Clinical Trial of Leuprorelin acetate in patients with SBMA (JASMITT-2)Double-blind Placebo-controlled Phase 2 Clinical Trial of TAP-144-SR (3M) in patients with Spinal and Bulbar Muscular Atrophy (SBMA) Spinal and Bulbar muscular atrophyIntervention type:DRUG. Intervention1:TAP-144-SR(3M) , Dose form:INJECTION, Route of administration:SUBCUTANEOUS. Control intervention1:placebo, Dose form:INJECTION, Route of administration:SUBCUTANEOUS.JASMITT Clinical Trial OfficeJichi med college, Chiba univ., Univ of Tokyo, Tokyo med & dental univ.Completed>=30 YEARS<70 YEARSMale100Phase 2Japan
4JPRN-UMIN000001455
2008/10/0123/10/2008Open clinical trial of Leuprorelin Acetate (SR) in patients with Kennedy-Alter-Sung syndrome (KAS) Kennedy-Alter-Sung syndrome (KAS)Leuprorelin acetate (SR) 11.25mg subcutaneous infection per 12 weeksDepartment of NeurologyChiba University Graduate School of MedicineNULL20years-oldNot applicableMale10Not selectedJapan
5JPRN-JMA-IIA00111
29/08/200722/02/2013Long Term Follow-up Phase III Clinical Trial of Leuprorelin acetate in Patients with SBMA (JASMITT)Long Term Follow-up Phase III Clinical Trial of TAP-144-SR (3M) in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) Spinal and Bulbar Muscular Atrophy (SBMA)Intervention type:DRUG. Intervention1:TAP-144-SR(3M), Dose form:INJECTION, Route of administration:SUBCUTANEOUS, intended dose regimen:every 12 week. Control intervention1:N.A., Dose form:NOT APPLICABLE, Route of administration:NOT APPLICABLE , Intended dose regimen:N.A..Gen SobueIchiro Yabe, Masashi Aoki, Imaharu Nakano, Kazuaki Kanai, Hidehiro Mizusawa, Tomotaka Yamamoto, Kazuko Hasegawa, Masatoyo Nishizawa, Hiroaki Miyajima, Norio Kanda, Kenji Nakajima, Akira Tsujino, Makoto UchinoCompleted>=30 YEARS<71 YEARSMale152Phase 3Japan
6JPRN-JMA-IIA00009
13/09/200624/08/2006Phase III Clinical Trial of Leuprorelin acetate in Patients with SBMA (JASMITT)Double-blind Placebo-controlled Phase III Clinical Trial of TAP-144-SR (3M) in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) Spinal and Bulbar Muscular Atrophy (SBMA)Intervention type:DRUG. Intervention1:TAP-144-SR(3M), Dose form:INJECTION, Route of administration:SUBCUTANEOUS. Control intervention1:placebo, Dose form:INJECTION, Route of administration:SUBCUTANEOUS.JASMITT Clinical Trial OfficeHokkaido University, Tohoku University, Jichi Medical College, Chiba University, University of Tokyo, Tokyo Medical and Dental University, NHO Sagamitara hospital, Niigata University, Hamamatsu Medical college, Kobe University, Tottori University, Nagasaki University, Kumamoto UniversityCompleted>=30 YEARS<70 YEARSMale170Phase 3Japan
7JPRN-UMIN000000474
2003/09/0101/09/2006Double-blind Placebo-controlled Clinical Trial of Leuprorelin acetate in Patients with Spinal and Bulbar Muscular Atrophy (SBMA) Spinal and bulbar muscular atrophy (SBMA)Leuprorelin acetate 3.75 mg subcutaneous injection every 4 weeks
Placebo subcutaneous injection every 4 weeks
Department of Neurology, Nagoya University School of MedicineNULLComplete: follow-up complete30years-old70years-oldMale40Phase 2Japan